Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Dermatologic 1Breast 1

Conditions

Melanoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Letrozole 9Fluorodeoxyglucose F18 7pembrolizumab 6Magnetic Resonance Spectroscopy 6atezolizumab 5Blood Specimen Collection 5Trastuzumab 4Oncolytic Virotherapy 4Biopsy 4Bevacizumab 4palbociclib 3durvalumab 3Vitamin D 3Taxes 3Saline Solution 3Radiotherapy 3Metformin 3Fish Oils 3Docosahexaenoic Acids 3Denosumab 3Carboplatin 3Albumin-Bound Paclitaxel 3pertuzumab 2olaparib 2bazedoxifene 2Vinorelbine 2Tamoxifen 2Sentinel Lymph Node Biopsy 2Positron-Emission Tomography 2Positron Emission Tomography Computed Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Propranolol × Breast × Clear all
NCT02013492 2022-12-06

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
1 enrolled
BreastDermatologicGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Hepatocellular, Melanoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡